# DA-1726 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/da-1726

> The next catalyst for DA-1726, sponsored by MetaVia Inc. (MTVA), is its topline data readout, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for DA-1726?

The next catalyst for DA-1726, sponsored by MetaVia Inc. (MTVA), is its topline data readout, Q1 2027. Press release filed with the SEC (EX-99): "All DA-1726 figures in this deck are from the Part 3B Day 109 interim dataset presented at the Precision Liver Symposium in November 2026; complete Part 3A and Part 3B topline data are expected in Q1 2027." [Calendar and source filings](https://sec-api.dev/pdufa/da-1726)

Source: Press release filed with the SEC (EX-99), accession 0001104659-26-126540, https://www.sec.gov/Archives/edgar/data/1638287/000110465926126540/mtva-ex99d2.htm (retrieved 2026-11-14). Last confirmed 2026-11-13. Cite: https://sec-api.dev/pdufa/da-1726#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | DA-1726 |
| Codes | DA-1726 |
| Sponsor | MetaVia Inc. (MTVA) https://sec-api.dev/companies/mtva/catalysts |
| Indications | [obesity](https://sec-api.dev/indications/obesity), obesity further demonstrating its best-in-class potential, obesity, to further explore the maximum tolerated dose |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Sep 2024: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 1. Indication: obesity.
- First seen 2025-03-20, last confirmed 2026-03-26.
- SEC Form 10-K (accession 0001558370-25-003386): "In September 2024, we announced positive top-line data from the" https://www.sec.gov/Archives/edgar/data/1638287/000155837025003386/mtva-20241231x10k.htm
- SEC Form 10-K (accession 0001104659-26-034911): "o In September 2024, we announced positive topline data from the single ascending dose ("SAD") Part 1 of our Phase 1 clinical trial evaluating DA-1726 while an additional SAD study and a multiple-ascending dose ("MAD") study were ongoing." https://www.sec.gov/Archives/edgar/data/1638287/000110465926034911/mtva-20251231x10k.htm
- SEC prospectus (424B) (accession 0001104659-26-004337): "In September 2024, we announced positive top-line data from the single ascending dose Part 1 of our Phase 1 trial evaluating DA-1726." https://www.sec.gov/Archives/edgar/data/1638287/000110465926004337/tm2528002-19_424b4.htm
- SEC prospectus (424B) (accession 0001104659-26-004337): "In September 2024, we announced positive top-line data from the planned single ascending dose ("SAD") Part 1 of our Phase 1 trial evaluating DA-1726 while an additional SAD study and MAD study were ongoing." https://www.sec.gov/Archives/edgar/data/1638287/000110465926004337/tm2528002-19_424b4.htm
- SEC registration statement (S-1) (accession 0001104659-26-000695): "In September 2024, we announced positive top-line data from the single ascending dose Part 1 of our Phase 1 trial evaluating DA-1726." https://www.sec.gov/Archives/edgar/data/1638287/000110465926000695/mtva-20250930xs1.htm
- SEC registration statement (S-1) (accession 0001104659-26-000695): "In September 2024, we announced positive top-line data from the planned single ascending dose ("SAD") Part 1 of our Phase 1 trial evaluating DA-1726 while an additional SAD study and MAD study were ongoing." https://www.sec.gov/Archives/edgar/data/1638287/000110465926000695/mtva-20250930xs1.htm
- SEC Form 10-Q (accession 0001104659-25-107726): "In September 2024, we announced positive top-line data from the single ascending dose Part 1 of our Phase 1 trial evaluating DA-1726." https://www.sec.gov/Archives/edgar/data/1638287/000110465925107726/mtva-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-010759): "In September 2024, we announced positive top-line data from the single ascending dose Part 1 of our Phase 1 trial evaluating DA-1726." https://www.sec.gov/Archives/edgar/data/1638287/000155837025010759/mtva-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-007749): "In September 2024, we announced positive top-line data from the single ascending dose Part 1 of our Phase 1 trial evaluating DA-1726." https://www.sec.gov/Archives/edgar/data/1638287/000155837025007749/mtva-20250331x10q.htm
- SEC Form 10-K (accession 0001558370-25-003386): "o In September 2024, we announced positive top-line data from the planned single ascending dose ("SAD") Part 1 of our Phase 1 trial evaluating DA-1726 while an additional SAD study and multiple-ascending dose ("MAD") study were ongoing." https://www.sec.gov/Archives/edgar/data/1638287/000155837025003386/mtva-20241231x10k.htm
- SEC Form 10-K (accession 0001558370-25-003386): "September 2024: Announced positive top-line data from the SAD Part 1 of our Phase 1 clinical trial evaluating DA-1726 for the treatment of obesity." https://www.sec.gov/Archives/edgar/data/1638287/000155837025003386/mtva-20241231x10k.htm
- SEC Form 10-K (accession 0001104659-26-034911): "In September 2024, we announced positive topline data from the single ascending dose Part 1 of our Phase 1 clinical trial." https://www.sec.gov/Archives/edgar/data/1638287/000110465926034911/mtva-20251231x10k.htm

### Apr 2025: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 1. Indication: obesity further demonstrating its best-in-class potential.
- First seen 2024-11-18, last confirmed 2026-03-26.
- Press release filed with the SEC (EX-99) (accession 0001558370-25-010658): "April 2025: Reported additional positive top-line results from the 4-week MAD Part 2 of its Phase 1 clinical trial of DA-1726 for the treatment of obesity further demonstrating its best-in-class potential." https://www.sec.gov/Archives/edgar/data/1638287/000155837025010658/mtva-20250807xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-010658): "April 2025: Announced positive top-line results from the 4-week MAD Part 2 of its Phase 1 clinical trial of DA-1726 for the treatment of obesity." https://www.sec.gov/Archives/edgar/data/1638287/000155837025010658/mtva-20250807xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-007740): "April 2025: Reported additional positive top-line results from the 4-week MAD Part 2 of its Phase 1 clinical trial of DA-1726 for the treatment of obesity further demonstrating its best-in-class potential." https://www.sec.gov/Archives/edgar/data/1638287/000155837025007740/mtva-20250514xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-007740): "April 2025: Announced positive top-line results from the 4-week MAD Part 2 of its Phase 1 clinical trial of DA-1726 for the treatment of obesity." https://www.sec.gov/Archives/edgar/data/1638287/000155837025007740/mtva-20250514xex99d1.htm
- SEC prospectus (424B) (accession 0001104659-26-004337): "In April 2025, we announced positive top-line data from the multiple ascending dose ("MAD") Part 2 study of our Phase 1 trial up to a 32 mg dose." https://www.sec.gov/Archives/edgar/data/1638287/000110465926004337/tm2528002-19_424b4.htm
- SEC prospectus (424B) (accession 0001104659-26-004337): "In April 2025, we announced positive top-line data from the MAD Part 2 study of our Phase 1 trial up to a 32 mg dose." https://www.sec.gov/Archives/edgar/data/1638287/000110465926004337/tm2528002-19_424b4.htm
- SEC prospectus (424B) (accession 0001104659-26-004337): "In April 2025, we announced positive top-line data from the Phase 1 MAD Part 2 up to 32 mg dose for Cohort 4." https://www.sec.gov/Archives/edgar/data/1638287/000110465926004337/tm2528002-19_424b4.htm
- SEC registration statement (S-1) (accession 0001104659-26-000695): "In April 2025, we announced positive top-line data from the multiple ascending dose ("MAD") Part 2 study of our Phase 1 trial up to a 32 mg dose." https://www.sec.gov/Archives/edgar/data/1638287/000110465926000695/mtva-20250930xs1.htm
- SEC registration statement (S-1) (accession 0001104659-26-000695): "In April 2025, we announced positive top-line data from the MAD Part 2 study of our Phase 1 trial up to a 32 mg dose." https://www.sec.gov/Archives/edgar/data/1638287/000110465926000695/mtva-20250930xs1.htm
- SEC registration statement (S-1) (accession 0001104659-26-000695): "In April 2025, we announced positive top-line data from the Phase 1 MAD Part 2 up to 32 mg dose for Cohort 4." https://www.sec.gov/Archives/edgar/data/1638287/000110465926000695/mtva-20250930xs1.htm
- SEC Form 10-Q (accession 0001104659-25-107726): "In April 2025, we announced positive top-line data from the multiple ascending dose ("MAD") Part 2 study of our Phase 1 trial." https://www.sec.gov/Archives/edgar/data/1638287/000110465925107726/mtva-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-010759): "In April 2025, we announced positive top-line data from the multiple ascending dose ("MAD") Part 2 study of our Phase 1 trial." https://www.sec.gov/Archives/edgar/data/1638287/000155837025010759/mtva-20250630x10q.htm

### Jul 2025: trial start

- Status: completed. Date confidence: month. Stage: 1. Indication: obesity, to further explore the maximum tolerated dose.
- First seen 2025-08-07, last confirmed 2026-03-26.
- Press release filed with the SEC (EX-99) (accession 0001558370-25-010658): "July 2025: Dosed the first patient in the 4-week 48 mg MAD cohort of the Phase 1 clinical trial of DA-1726, for the treatment of obesity, to further explore the maximum tolerated dose." https://www.sec.gov/Archives/edgar/data/1638287/000155837025010658/mtva-20250807xex99d1.htm
- SEC prospectus (424B) (accession 0001104659-26-004337): "We dosed the first patient in the 48 mg, MAD cohort of our Phase 1 clinical trial of DA-1726 in July 2025 and we extended the clinical trial for this 48 mg, MAD cohort to eight weeks from four weeks to further explore the non-titrated maximum tolerated dose, explore safety and other primary, secondary and exploratory endpoints over a longer treatment duration, and evaluate longer-term early efficacy." https://www.sec.gov/Archives/edgar/data/1638287/000110465926004337/tm2528002-19_424b4.htm
- SEC registration statement (S-1) (accession 0001104659-26-000695): "We dosed the first patient in the 48 mg, MAD cohort of our Phase 1 clinical trial of DA-1726 in July 2025 and we extended the clinical trial for this 48 mg, MAD cohort to eight weeks from four weeks to further explore the non-titrated maximum tolerated dose, explore safety and other primary, secondary and exploratory endpoints over a longer treatment duration, and evaluate longer-term early efficacy." https://www.sec.gov/Archives/edgar/data/1638287/000110465926000695/mtva-20250930xs1.htm
- SEC registration statement (S-1) (accession 0001104659-26-000695): "We dosed the first patient in the 48 mg, MAD cohort of our Phase 1 clinical trial of DA-1726 in July 2025 and we extended the clinical" https://www.sec.gov/Archives/edgar/data/1638287/000110465926000695/mtva-20250930xs1.htm
- SEC Form 10-Q (accession 0001104659-25-107726): "We dosed the first patient in the 48 mg, MAD cohort of our Phase 1 clinical trial of DA-1726 in July 2025 and we extended the clinical trial for this 48 mg, MAD cohort to 8 weeks from 4 weeks to further explore the non-titrated maximum tolerated dose, explore safety and other primary, secondary and exploratory endpoints over a longer treatment duration, and evaluate longer-term early efficacy." https://www.sec.gov/Archives/edgar/data/1638287/000110465925107726/mtva-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-010759): "In July 2025, we dosed the first patient in the 48 mg, MAD cohort of our Phase 1 clinical trial of DA-1726." https://www.sec.gov/Archives/edgar/data/1638287/000155837025010759/mtva-20250630x10q.htm
- SEC Form 10-K (accession 0001104659-26-034911): "We dosed the first patient in the non-titrated 48 mg, MAD cohort of our Phase 1 clinical trial in July 2025, and we extended the clinical trial for this 48 mg, MAD cohort to eight weeks from four weeks to further explore the non-titrated maximum tolerated dose, explore safety and" https://www.sec.gov/Archives/edgar/data/1638287/000110465926034911/mtva-20251231x10k.htm
- SEC Form 10-K (accession 0001104659-26-034911): "We dosed the first patient in the 48 mg, MAD cohort of our Phase 1 clinical trial in July 2025, and we extended the clinical trial for this 48 mg, MAD cohort to eight weeks from four weeks to further explore the non-titrated maximum tolerated dose, explore safety and other primary, secondary and exploratory endpoints over a longer treatment duration, and evaluate longer-term early efficacy." https://www.sec.gov/Archives/edgar/data/1638287/000110465926034911/mtva-20251231x10k.htm

### Q4 2025: topline data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2025-07-09, last confirmed 2025-11-06.
- Press release filed with the SEC (EX-99) (accession 0001558370-25-010415): "Top-Line Data Expected in the Fourth Quarter of 2025" https://www.sec.gov/Archives/edgar/data/1638287/000155837025010415/mtva-20250806xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-010415): "Top-line data is expected in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1638287/000155837025010415/mtva-20250806xex99d1.htm
- SEC Form 8-K (accession 0001558370-25-009139): "Top-line data is expected in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1638287/000155837025009139/mtva-20250709x8k.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-009139): "Top-Line Data Expected in the Fourth Quarter of 2025" https://www.sec.gov/Archives/edgar/data/1638287/000155837025009139/mtva-20250709xex99d1.htm
- SEC Form 10-Q (accession 0001104659-25-107726): "Top-line data of the 48 mg, MAD cohort is expected in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1638287/000110465925107726/mtva-20250930x10q.htm
- SEC Form 10-Q (accession 0001104659-25-107726): "Top-line data is expected in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1638287/000110465925107726/mtva-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-010759): "Top-line data of the 48 mg MAD cohort is expected in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1638287/000155837025010759/mtva-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-010759): "Top-line data is expected in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1638287/000155837025010759/mtva-20250630x10q.htm

### January 5, 2026: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 1. Indication: Obesity.
- First seen 2025-08-07, last confirmed 2026-03-26.
- SEC prospectus (424B) (accession 0001104659-26-004337): "On January 5, 2026, we announced positive topline data of Phase 1 MAD Part 2 non-titrated 48 mg Cohort 5 clinical trial of DA-1726." https://www.sec.gov/Archives/edgar/data/1638287/000110465926004337/tm2528002-19_424b4.htm
- SEC registration statement (S-1) (accession 0001104659-26-000695): "On January 5, 2026, we announced positive topline data of Phase 1 MAD Part 2 non-titrated 48 mg Cohort 5 clinical trial of DA-1726." https://www.sec.gov/Archives/edgar/data/1638287/000110465926000695/mtva-20250930xs1.htm
- SEC Form 10-K (accession 0001104659-26-034911): "On January 5, 2026, we announced positive topline data of non-titrated 48 mg, MAD cohort of our Phase 1 clinical trial, and the results show robust early weight loss, statistically significant reductions in waist circumference, strong improvements in glucose control, and meaningful reductions in liver stiffness, alongside a favorable safety and tolerability profile." https://www.sec.gov/Archives/edgar/data/1638287/000110465926034911/mtva-20251231x10k.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-010658): "Dosed the First Patient in the 8-Week 48 mg MAD Cohort of its Phase 1 Clinical Trial to Further Explore Maximum Tolerated Dose of DA-1726 for the Treatment of Obesity; Top-Line Data Expected in the Fourth Quarter of 2025" https://www.sec.gov/Archives/edgar/data/1638287/000155837025010658/mtva-20250807xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-107447): "Dosed the First Patient in the 8-Week 48 mg MAD Cohort of its Phase 1 Clinical Trial to Further Explore Non-Titrated Maximum Tolerated Dose of DA-1726 for the Treatment of Obesity; Top-Line Data Expected by Year-End 2025" https://www.sec.gov/Archives/edgar/data/1638287/000110465925107447/mtva-20251106xex99d1.htm
- SEC Form 10-K (accession 0001104659-26-034911): "o On January 5, 2026, we announced positive topline data from our non-titrated 48 mg, MAD cohort 5 Part 2 of the Phase 1 clinical trial." https://www.sec.gov/Archives/edgar/data/1638287/000110465926034911/mtva-20251231x10k.htm
- SEC Form 10-K (accession 0001104659-26-034911): "Topline results from the Phase 1 MAD Part 1 Study.We have reported positive topline up to eight week results from the MAD Part 2 of our Phase 1 clinical trial in obese, otherwise healthy patients on January 5, 2026." https://www.sec.gov/Archives/edgar/data/1638287/000110465926034911/mtva-20251231x10k.htm
- SEC prospectus (424B) (accession 0001104659-26-004337): "We have reported positive top-line up to eight-week results from the Phase 1 MAD Part 2 clinical trial in obese, otherwise healthy patients on January 5, 2026." https://www.sec.gov/Archives/edgar/data/1638287/000110465926004337/tm2528002-19_424b4.htm
- SEC registration statement (S-1) (accession 0001104659-26-000695): "We have reported positive top-line up to eight-week results from the Phase 1 MAD Part 2 clinical trial in obese, otherwise healthy patients on January 5, 2026." https://www.sec.gov/Archives/edgar/data/1638287/000110465926000695/mtva-20250930xs1.htm

### April 10, 2026: trial start

- Status: completed. Date confidence: exact. Stage: 1.
- First seen 2026-03-26, last confirmed 2026-08-06.
- SEC Form 8-K (accession 0001104659-26-041784): "On April 10, 2026, MetaVia Inc. (the "Company") issued a press release announcing that the first patient has been dosed in Part 3 of its Phase 1 clinical trial evaluating DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors." https://www.sec.gov/Archives/edgar/data/1638287/000110465926041784/mtva-20260410x8k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-041784): "CAMBRIDGE, Mass., April 10, 2026 - MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that the first patient has been dosed in Part 3 of its Phase 1 clinical trial evaluating DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors." https://www.sec.gov/Archives/edgar/data/1638287/000110465926041784/mtva-20260410xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-091981): "April 2026: Dosed the first patient in Part 3 of the 16-week Phase 1 clinical trial evaluating DA-1726 in obese, otherwise healthy adults using one-step titration to 48 mg and two-step titration to 64 mg to safely achieve higher target doses and optimize tolerability." https://www.sec.gov/Archives/edgar/data/1638287/000110465926091981/mtva-20260806xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-061148): "April 2026: Dosed the first patient in Part 3 of the Phase 1 clinical trial evaluating DA-1726 in obese, otherwise healthy adults, consisting of two 16-week titration cohorts designed to evaluate one-step dose titration to 48 mg and two-step dose titration to 64 mg, designed to safely achieve higher target doses and further optimize tolerability." https://www.sec.gov/Archives/edgar/data/1638287/000110465926061148/mtva-20260514xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-034907): "o Dosing of the first patient in the company's Phase 1 Part 3, 16-week titration studies, evaluating titration to 48 mg in one step and 64 mg via a two-step regimen, is expected in April of 2026." https://www.sec.gov/Archives/edgar/data/1638287/000110465926034907/mtva-20260326xex99d1.htm

### Q4 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 1.
- First seen 2026-05-14, last confirmed 2026-10-13.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-115300): "Sarah joins MetaVia at an important time as we prepare for the anticipated fourth quarter 2026 topline data readout from Part 3 of our Phase 1 clinical trial of DA-1726, evaluating higher target doses of 48 mg and 64 mg." https://www.sec.gov/Archives/edgar/data/1638287/000110465926115300/mtva-ex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-091981): ""Most recently, all active patients in both cohorts of our ongoing Phase 1 Part 3 study successfully reached the highest planned dose levels of 48 mg and 64 mg, representing an important execution milestone as we prepare for our 16-week topline data readout, expected in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1638287/000110465926091981/mtva-20260806xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-091981): "o Data readout from Phase 1 Part 3, 16-week titration studies, evaluating titration to 48 mg in one step and 64 mg via a two-step regimen, is expected in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1638287/000110465926091981/mtva-20260806xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-061148): "o Data readout from Phase 1 Part 3, 16-week titration studies, evaluating titration to 48 mg in one step and 64 mg via a two-step regimen, is expected in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1638287/000110465926061148/mtva-20260514xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-091981): "16-Week Topline Data Expected in the Fourth Quarter of 2026" https://www.sec.gov/Archives/edgar/data/1638287/000110465926091981/mtva-20260806xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-082116): "With all patients now on their target doses, we remain focused on completing treatment and reporting topline data in the fourth quarter of 2026."" https://www.sec.gov/Archives/edgar/data/1638287/000110465926082116/tm2620006d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-106156): "We anticipate reporting 16-week topline data in the fourth quarter of this year, followed by 24-week topline results in the first quarter of 2027."" https://www.sec.gov/Archives/edgar/data/1638287/000110465926106156/mtva-20260909xex99d1.htm

### Q4 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 1.
- First seen 2026-03-26, last confirmed 2026-03-26.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-034907): "Having recently received Institutional Review Board (IRB) approval from the Clinical Pharmacology of Miami, we expect to initiate dosing in our Phase 1 Part 3, 16-week titration studies evaluating escalation to 48 mg in a single step and 64 mg using a two-step regimen in April, with data anticipated in the fourth quarter of 2026."" https://www.sec.gov/Archives/edgar/data/1638287/000110465926034907/mtva-20260326xex99d1.htm

### November 5, 2026: interim data readout

- Status: completed, positive. Date confidence: exact. Stage: 1.
- First seen 2025-03-20, last confirmed 2026-11-12.
- SEC Form 8-K (accession 0001104659-26-125964): "On November 12, 2026, MetaVia Inc. (the "Company") issued a press release announcing additional positive data from the previously reported interim analysis of Part 3B of its Phase 1 clinical trial of DA-1726, a novel oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors." https://www.sec.gov/Archives/edgar/data/1638287/000110465926125964/mtva-20261112x8k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-125964): "CAMBRIDGE, Mass., November 12, 2026 - MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming liver-related cardiometabolic diseases, today announced additional positive data from the previously reported interim analysis of Part 3B of its Phase 1 clinical trial of DA-1726, a novel oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors." https://www.sec.gov/Archives/edgar/data/1638287/000110465926125964/mtva-ex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-123110): "CAMBRIDGE, Mass., November 5, 2026 - MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming liver-related cardiometabolic diseases, today announced positive interim data from Part 3B of its Phase 1 clinical trial of DA-1726, a novel oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors." https://www.sec.gov/Archives/edgar/data/1638287/000110465926123110/mtva-ex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-003344): "The planned Phase 1 Part 3 will evaluate early proof of concept, with the first patient expected to be enrolled during the fourth quarter of 2025, followed by an interim data readout in or around mid-2026 and top-line results are expected in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1638287/000155837025003344/mtva-20250320xex99d1.htm

### Q1 2027: topline data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2026-11-05, last confirmed 2026-11-13.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-126540): "All DA-1726 figures in this deck are from the Part 3B Day 109 interim dataset presented at the Precision Liver Symposium in November 2026; complete Part 3A and Part 3B topline data are expected in Q1 2027." https://www.sec.gov/Archives/edgar/data/1638287/000110465926126540/mtva-ex99d2.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-126540): "Topline expected Q1 2027 SURMOUNT-1 (Ph.3, obesity) TRIUMPH-1 (Ph.3, obesity) Lilly Ph.2 (obesity) SYNCHRONIZE-1 (Ph.3, obesity) MOMENTUM (Ph.2, obesity);" https://www.sec.gov/Archives/edgar/data/1638287/000110465926126540/mtva-ex99d2.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-123110): "Topline expected Q1 2027 SURMOUNT-1 (Ph.3, obesity) TRIUMPH-1 (Ph.3, obesity) Lilly Ph.2 (obesity) SYNCHRONIZE-1 (Ph.3, obesity) MOMENTUM (Ph.2, obesity);" https://www.sec.gov/Archives/edgar/data/1638287/000110465926123110/mtva-ex99d2.htm

## Same indication

- [ISEMBYLD (apitegromab)](https://sec-api.dev/pdufa/apitegromab) (SRRK)
- [CRB-913](https://sec-api.dev/pdufa/crb-913) (CRBP)
- [RT-114](https://sec-api.dev/pdufa/rt-114) (RANI)
- [RaniPill (RT-116)](https://sec-api.dev/pdufa/rt-116) (RANI)
- [Wegovy (semaglutide)](https://sec-api.dev/pdufa/semaglutide) (NVO)
- [VK2735](https://sec-api.dev/pdufa/vk2735) (VKTX)
- [WVE-007](https://sec-api.dev/pdufa/wve-007) (WVE)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/da-1726.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "DA-1726 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/da-1726

```bibtex
@misc{secapidev_pdufa_da_1726_20261116,
  title        = {DA-1726 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/da-1726}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_da_1726_20261116","title":"DA-1726 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/da-1726","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
